GlassScriptPhysician profile
Amr Shayeb
NPI 1790922136
$15,678.71
in general payments reported to CMS, 2019-2025
20 companies · $302 in 2025
The $302 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,602 · 2020: $609 · 2021: $2,971 · 2022: $65.39 · 2023: $6,567 · 2024: $563 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,689 · Travel and Lodging: $1,613 · Food and Beverage: $1,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,688.94 |
| Travel and Lodging | $1,613.00 |
| Food and Beverage | $1,130.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanos Medical | $7,945.04 | 2019-2021 | |
| Intuitive Surgical, INC. | $6,228.53 | 2023 | Davinci Xi, Da Vinci Surgical System |
| Astellas Pharma US INC | $412.73 | 2023-2025 | Veozah |
| Hologic Sales and Service, LLC | $314.45 | 2019-2025 | Fluent Fluid Management System, Myosure Tissue Removal Device, Aptima |
| Organon LLC | $117.94 | 2022-2025 | Nexplanon |
| Baxter Healthcare | $92.68 | 2023-2025 | Perclot, Floseal |
| Sumitomo Pharma America, INC. | $92.17 | 2023-2025 | Myfembree |
| Abbvie INC. | $80.97 | 2019-2020 | |
| Biogen, INC. | $76.61 | 2025 | Zurzuvae |
| Agile Therapeutics, INC. | $62.57 | 2023 | Twirla |
| Merck Sharp & Dohme LLC | $41.37 | 2019-2024 | Gardasil 9, Gardasil |
| Kerecis Limited | $37.87 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Amag Pharmaceuticals, INC. | $37.22 | 2019 | |
| Therapeuticsmd, INC. | $24.84 | 2022 | |
| Smith+Nephew, INC. | $24.52 | 2023 | Pico 7 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $24.11 | 2020 | |
| Kci USA, INC. | $19.00 | 2019 | |
| Allergan, INC. | $16.13 | 2019 | |
| Shield Therapeutics INC | $15.31 | 2023 | Accrufer |
| Lupin INC. | $14.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amr Shayeb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.